Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2024-02-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于转让控股子公司股权被动形成财务资助的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the passive formation of financial assistance due to the transfer of equity in its controlling subsidiaries. It details the financial assistance provided to two subsidiaries, including amounts, terms, and risk analysis. The document includes specifics about the equity transfer, financial support agreements, and board opinions. It is a regulatory announcement about financing activities related to subsidiaries, not a full financial report or earnings release. It does not contain comprehensive financial statements or quarterly results but focuses on capital/financing updates related to equity transfers and financial support. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 4749 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2024-02-29 Chinese
监事会关于第九届监事会第十次会议相关事项的意见
Board/Management Information Classification · 90% confidence The document is a short statement from the Supervisory Board (监事会) of Shenzhen Haiwang Bioengineering Co., Ltd. expressing an opinion on a specific matter discussed in their meeting, specifically regarding external guarantees. It is not a full financial report, audit report, or regulatory filing. It is a formal opinion related to board/management oversight activities. Given the content and nature, it fits best under Board/Management Information (MANG), which covers announcements related to company board or senior management matters. The document length is very short and does not contain financial data or detailed report content, so it is not an Annual Report or Audit Report. Therefore, the classification is MANG with high confidence.
2024-02-29 Chinese
关于提供财务资助的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the progress of financial assistance provided to subsidiaries and related financial support matters. It includes details about board meetings approving financial assistance, amounts involved, risk analysis, and repayment status. The document is relatively short (1701 characters) and focuses on updates about financial support activities rather than presenting full financial statements or comprehensive financial performance data. It does not contain quarterly or annual financial results, nor is it a transcript, audit report, or management discussion. The content fits the description of a Capital/Financing Update (CAP) as it provides updates on financing activities and capital support to subsidiaries. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2024-02-29 Chinese
关于担保延续构成对外担保的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the continuation of guarantees constituting external guarantees. It discusses the company's provision of guarantees for its subsidiaries and related entities, including details about share transfers, guarantee amounts, terms, and risk mitigation measures. The document includes financial data related to the guaranteed entities but does not present comprehensive financial statements or a full financial report. It is not an annual or interim report, earnings release, or audit report. It is a regulatory announcement about guarantees and related corporate actions, fitting the category of a Regulatory Filing (RNS).
2024-02-29 Chinese
关于收购控股子公司少数股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the acquisition of minority equity interests in subsidiaries by the company. It details the transaction overview, parties involved, shareholding changes, financial data of subsidiaries, terms of the equity repurchase agreements, payment schedules, and impact on the company. It is a formal disclosure of a corporate transaction involving capital structure changes but does not contain comprehensive financial statements or quarterly/yearly financial results. It is not an earnings release, annual report, or interim report. It is not a merger or acquisition filing in the sense of a takeover or merger proxy statement but rather a capital transaction involving share repurchase from an investor. The document is a detailed announcement of a capital/financing update related to the company's equity structure and investment activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (6214 characters) and content support this classification with high confidence.
2024-02-29 Chinese
第九届董事局第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 12th meeting of the 9th Board of Directors of Shenzhen Haiwang Bioengineering Co., Ltd. It details the meeting date, voting results, and references to other announcements published elsewhere. The content focuses on board decisions regarding acquisitions, guarantees, and convening a shareholders' meeting. There is no financial data, earnings information, or detailed report content. The document is clearly an announcement of board meeting resolutions, which fits the category of Board/Management Information (MANG). The document length is short (1074 characters), and it is not a report or presentation but an official announcement of board decisions.
2024-02-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.